Editing Escaline (section)

==Effects==
The effects of escaline and related [[mescaline]] analogues in humans were first described by [[Alexander Shulgin]].<ref name="PiHKAL" /> In his book ''[[PiHKAL|PiHKAL (Phenethylamines i Have Known And Loved)]]'', Shulgin lists the dosage range as 40 to 60{{nbsp}}mg of the [[hydrochloride]] [[salt (chemistry)|salt]] taken [[oral administration|orally]].<ref name="PiHKAL">{{Cite web|url=https://www.erowid.org/library/books_online/pihkal/pihkal072.shtml|title=Erowid Online Books : "PIHKAL" - #72 E| website=www.erowid.org|access-date=2024-02-02|archive-date=2023-05-06|archive-url= https://web.archive.org/web/20230506192807/https://www.erowid.org/library/books_online/pihkal/pihkal072.shtml|url-status=live}}</ref><ref name="HalberstadtChathaKlein2020" /> The duration of action was stated to be 8 to 12{{nbsp}}hours.<ref name="PiHKAL" /> Escaline is approximately 5- to 8-fold more [[potency (pharmacology)|potent]] than mescaline in humans.<ref name="BlaazerSmidKruse2008">{{cite journal | vauthors = Blaazer AR, Smid P, Kruse CG | title = Structure-activity relationships of phenylalkylamines as agonist ligands for 5-HT(2A) receptors | journal = ChemMedChem | volume = 3 | issue = 9 | pages = 1299–1309 | date = September 2008 | pmid = 18666267 | doi = 10.1002/cmdc.200800133 | url = https://www.thevespiary.org/rhodium/Rhodium/Vespiary/talk/files/1981-Structure%E2%80%93Activity-Relationships-of-Phenylalkylamines-asAgonist-Ligands-for-5-HT2A-Receptors807f.pdf | archive-url = https://web.archive.org/web/20190721062032/https://www.thevespiary.org/rhodium/Rhodium/Vespiary/talk/files/1981-Structure%E2%80%93Activity-Relationships-of-Phenylalkylamines-asAgonist-Ligands-for-5-HT2A-Receptors807f.pdf | archive-date = 21 July 2019 }}</ref>